Cytogenetic abnormalities, latencies, and OS of patients with t-MNs after RT monotherapy
| Karyotype . | Number of patients (%) . | Median latency, y (IQR) . | 1-y OS % (95% CI) . | 5-y OS % (95% CI) . |
|---|---|---|---|---|
| Normal | 26 (24%) | 7.2 (3-10) | 77 (62-95) | 41 (25-66) |
| Clonal abnormalities | ||||
| Abnormal 5, 7, or both* | 49 (45%) | 6.6 (4-11) | 37 (24-53) | 2 (0-15) |
| Abnormal 5 | 22 | 4.4 (3-11) | 36 (21-63) | 5 (1-31) |
| Abnormal 7 | 11 | 6.6 (6-10) | 46 (24-87) | 0 |
| Abnormal 5 and 7 | 16 | 6.5 (5-8) | 31 (15-65) | 0 |
| Recurring translocations | 15 (14%) | 2.3 (2-5) | 55 (34-90) | 55 (34-90) |
| t(8;21) | 1 | 2.1 | 100 | 100 |
| t(21q22) | 2 | 3.7 | 0 | 0 |
| t(15;17) | 4 | 2.2 | 50 | 50 |
| inv(16) | 5 | 2 | 75 | 75 |
| t(16;16) | 1 | 2.3 | 100 | 100 |
| t(11q23.3)/KMT2A | 1 | 7.1 | 0 | 0 |
| inv(3q) | 1 | 35 | 100 | NA |
| Trisomy 8 | 11 (10%) | 6.5 (4-15) | 55 (32-94) | 36 (17-80) |
| Other clonal abnormalities | 8 (7%) | 12.9 (9-45) | 63 (37-100) | 13 (2-78) |
| All cytogenetic analyses | 109 | 6.5 (3-11) | 52 (44-63) | 22 (15-32) |
| Karyotype . | Number of patients (%) . | Median latency, y (IQR) . | 1-y OS % (95% CI) . | 5-y OS % (95% CI) . |
|---|---|---|---|---|
| Normal | 26 (24%) | 7.2 (3-10) | 77 (62-95) | 41 (25-66) |
| Clonal abnormalities | ||||
| Abnormal 5, 7, or both* | 49 (45%) | 6.6 (4-11) | 37 (24-53) | 2 (0-15) |
| Abnormal 5 | 22 | 4.4 (3-11) | 36 (21-63) | 5 (1-31) |
| Abnormal 7 | 11 | 6.6 (6-10) | 46 (24-87) | 0 |
| Abnormal 5 and 7 | 16 | 6.5 (5-8) | 31 (15-65) | 0 |
| Recurring translocations | 15 (14%) | 2.3 (2-5) | 55 (34-90) | 55 (34-90) |
| t(8;21) | 1 | 2.1 | 100 | 100 |
| t(21q22) | 2 | 3.7 | 0 | 0 |
| t(15;17) | 4 | 2.2 | 50 | 50 |
| inv(16) | 5 | 2 | 75 | 75 |
| t(16;16) | 1 | 2.3 | 100 | 100 |
| t(11q23.3)/KMT2A | 1 | 7.1 | 0 | 0 |
| inv(3q) | 1 | 35 | 100 | NA |
| Trisomy 8 | 11 (10%) | 6.5 (4-15) | 55 (32-94) | 36 (17-80) |
| Other clonal abnormalities | 8 (7%) | 12.9 (9-45) | 63 (37-100) | 13 (2-78) |
| All cytogenetic analyses | 109 | 6.5 (3-11) | 52 (44-63) | 22 (15-32) |
NA, not available.
Seventeen patients in this category also had loss of 17p.